Key Takeaways
- Dr. Srishti Gupta has been appointed as CEO of Idorsia, effective July 1, 2025.
- Gupta has served on Idorsia’s board since 2021, bringing extensive knowledge of the company and its products.
- She has over 20 years of experience in global health and biopharmaceutical innovation, including 18 years at McKinsey & Company.
New Leadership at Idorsia
Idorsia, a Swiss pharmaceutical company, has announced the appointment of Dr. Srishti Gupta as its new CEO, a position she will officially assume on July 1, 2025. With her experience on the board of directors since 2021, Dr. Gupta has developed a comprehensive understanding of Idorsia’s operations, its people, and its product portfolio.
Dr. Gupta is recognized for her extensive background in global health and biopharmaceutical innovation, boasting over two decades of experience. She has a proven track record in advancing science-based solutions across various sectors of medicine, strategy, and healthcare systems. During her career, she has led impactful teams and consulted with companies across therapeutic areas, focusing on portfolio development, business strategy, and enhancing patient access to treatments.
Her previous experience includes an impressive 18-year tenure at McKinsey & Company, where she held senior leadership roles within the pharmaceutical and global health divisions. In addition to her consultancy work, Dr. Gupta has held leadership positions on the boards of several biotechnology firms and global health partnerships, emphasizing her dedication to translating scientific advancements into real-world patient benefits.
With her appointment, Idorsia aims to leverage Dr. Gupta’s expertise and insights to further enhance its strategic direction and innovation in the pharmaceutical sector.
The content above is a summary. For more details, see the source article.
